| Dr Sophie Soltani, PSYD | |
|
745 Buena Vista Ave, Alameda, CA 94501-2115 | |
| (510) 523-4300 | |
| Not Available |
| Full Name | Dr Sophie Soltani |
|---|---|
| Gender | Female |
| Speciality | Psychologist |
| Location | 745 Buena Vista Ave, Alameda, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366756785 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | PSY18056 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sophie Soltani, PSYD 745 Buena Vista Ave, Alameda, CA 94501-2115 Ph: (510) 523-4300 | Dr Sophie Soltani, PSYD 745 Buena Vista Ave, Alameda, CA 94501-2115 Ph: (510) 523-4300 |
News Archive
Despite dramatically improved survival rates for childhood acute lymphoblastic leukemia, relapse remains a leading cause of death from the disease. Work led by St. Jude Children's Research Hospital investigators identified mutations in a gene named CREBBP that may help the cancer resist steroid treatment and fuel ALL's return.
Quantifying tablet disintegration profiles in situ and in real time enables scientists to reliably understand the breakage and dispersion mechanisms that govern API release rates. This essential process knowledge can support the prediction of in vivo drug release profiles during formulation development, and help identify the root cause of inconsistencies during release testing.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
Nymox Pharmaceutical Corporation outlined today the Company's development program for the Company's lead drug candidate, NX-1207, currently in Phase 3 trials in the U.S. for the treatment of benign prostatic hyperplasia (BPH). The drug has been successful in a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs.
Prophylactic antibiotics significantly reduce the risk of serious bacterial infections in children during the critical first month of treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer, according to a U.S. and Canadian study led by investigators from Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
› Verified 9 days ago
Leonard Ferrara, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1150 Ballena Blvd, Suite113, Alameda, CA 94501 Phone: 510-599-8392 | |
Daniel J Libby, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1505 Webster St, Alameda, CA 94501 Phone: 516-680-8362 | |
Dr. Tucker Peck, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 2103 San Jose Ave, Alameda, CA 94501 Phone: 520-485-9411 Fax: 844-227-8699 | |
Hawlan Ng, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1415 Webster St Unit 3076, Alameda, CA 94501 Phone: 510-409-3928 | |
Mrs. Nusrat Sultan, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1025 Atlantic Ave Ste 101, Alameda, CA 94501 Phone: 510-268-8120 | |
Joyce Ray Saad, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 2258 Santa Clara Ave, Suite 4, Alameda, CA 94501 Phone: 510-522-3076 | |
Dr. Merry Thomas, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 2245 Santa Clara Ave Ste 200, Alameda, CA 94501 Phone: 510-749-9040 Fax: 510-864-8040 |